Maxime Ronot

🚨EASL CPG on the management of HCC in @JHepatology
Major update!

✅ LI-RADS endorsed
✅ Refined treatment algo
✅ More evidence supporting locoregional treatments
✅ Up-to-date discussions

👉bit.ly/3VKZmcy

Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies

Amazing collective work 💪
Everything there is to know, and more!
+ a new set of imaging criteria to play with ⬇️
thelancet.com/journals/langa… @ValdigGroup
@RautouE

LI-RADS & pathology in resected HCC in @radiology_rsna

✅360 pts
✅LR-M associated with recurrence & death
✅≥ 1 nontargetoid feature associated with recurrence
😎 @LIRADS5

@cannella_rob @A_Beaufrere @SebastienMule @marco_dioguardi @Caldera60373705

shorturl.at/bkyE9

Clinical and financial burden of nonHCC during surveillance of cirrhosis by Pierre Nahon et al. in @HEP_Journal

✅Incidence of nonHCC = twice that of HCC
✅Recall procedures ➡️diagnosis in 2/3
✅nonHCC ↗️surveillance cost
⚠️Important for future trials!

tinyurl.com/2p987pbm

Automated CT LI-RADS with machine learning @JHEP_Reports with @SebastienMule @LIRADS5

✅ML assessed major LI-RADS features
✅LR-5 diagnosed with high specificity and good sensitivity.
✅Stepwise ML+radiologist improved the performance for LR-5

doi.org/10.1016%2Fj.jh…